89bio Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" 89bio stock.
View analyst ratings for 89bio or view top-rated stocks.

7 brokers have issued 1 year target prices for 89bio's stock. Their ETNB stock forecasts range from $12.00 to $60.00. On average, they expect 89bio's share price to reach $34.88 in the next twelve months. This suggests a possible upside of 905.0% from the stock's current price.
View analysts' price targets for 89bio or view top-rated stocks among Wall Street analysts.

89bio's stock was trading at $13.07 at the beginning of 2022. Since then, ETNB shares have decreased by 73.5% and is now trading at $3.47.
View the best growth stocks for 2022 here.

89bio is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for 89bio.

89bio, Inc. (NASDAQ:ETNB) released its quarterly earnings results on Wednesday, May, 11th. The company reported ($1.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.38) by $0.12.
View 89bio's earnings history.

Some companies that are related to 89bio include Thorne HealthTech (THRN), PepGen (PEPG), Provention Bio (PRVB), LianBio (LIAN), Verona Pharma (VRNA), AC Immune (ACIU), Inventiva (IVA), Alpine Immune Sciences (ALPN), Prelude Therapeutics (PRLD), InterCure (INCR), Rallybio (RLYB), Aadi Bioscience (AADI), KalVista Pharmaceuticals (KALV), Zomedica (ZOM) and Sernova (SEOVF).
View all of ETNB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), (HON), Raytheon Technologies (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO).

(ETNB) raised $70 million in an initial public offering on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

89bio trades on the NASDAQ under the ticker symbol "ETNB."

89bio's stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (8.76%), BlackRock Inc. (4.53%), Bank of America Corp DE (2.06%), Vanguard Group Inc. (1.99%), Pekin Hardy Strauss Inc. (1.77%) and Renaissance Technologies LLC (1.29%). Company insiders that own 89bio stock include Gregory Grunberg, Longitude Capital Partners Iii, Ollin B Sykes, Orbimed Advisors Llc, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins.
View institutional ownership trends for 89bio.

ETNB stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Vanguard Group Inc., Charles Schwab Investment Management Inc., and Northern Trust Corp. Company insiders that have sold 89bio company stock in the last two years include Gregory Grunberg, Orbimed Advisors Llc, Ram Waisbourd, and Ryan Martins.
View insider buying and selling activity for 89bio or view top insider-selling stocks.

ETNB stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Renaissance Technologies LLC, Pekin Hardy Strauss Inc., BlackRock Inc., JPMorgan Chase & Co., Goldman Sachs Group Inc., GSA Capital Partners LLP, and XTX Topco Ltd. Company insiders that have bought 89bio stock in the last two years include Longitude Capital Partners Iii, Ollin B Sykes, Ra Capital Management, LP, and Rohan Palekar.
View insider buying and selling activity for 89bio or or view top insider-buying stocks.

Shares of ETNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ETNB stock can currently be purchased for approximately $3.47.

89bio (NASDAQ:ETNB) has a market capitalization of $70.62 million. The company earns $-90.12 million in net income (profit) each year or ($5.00) on an earnings per share basis.

89bio employs 41 workers across the globe.

89bio's mailing address is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. The official website for 89bio is www.89bio.com. The company can be reached via phone at 415-500-4614 or via email at [email protected].